Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts

CAMBRIDGE, Mass .– (BUSINESS WIRE) – Takeda (TSE: 4502 / NYSE: TAK) BioMed Realty has about 15,000 square feet of research and development (R&D) and office space to be built at 585 Third Street in Kendall Square. The state-of-the-art facility will allow Takeda, the largest life sciences employer in Massachusetts, to create a purpose-built R&D facility with future laboratories featuring modern design elements and upgraded technology to support the company in its efforts to advance innovation for patients. The new facility will support Takeda’s efforts to redeem the future by adopting flexible workspaces. The company will also expand its existing space in 650 East Kendall to include two additional floors, making Takeda the sole laboratory and office tenant in that building.

The agreement with BioMed Realty further expands Takeda’s presence in Kendall Square, a hub for life sciences, and unites Takeda’s Global R&D center in Cambridge and co-locating R&D with businesses and other operations. Takeda will eventually transition teams from Central Square to Kendall Square over time. Takeda will maintain a presence in Lexington as its suburban location.

“Takeda’s purpose to achieve ‘better health for people, a brighter future for the world’ is embedded into all our decision-making, including real estate. ” Unit and US country head. “Our goal is to build an enriching and inclusive workspace that will inspire, foster learning and innovation, harness data and digital technologies and emphasize well-being. ”

The new building is designed with sustainability in mind and will require LEED Gold or higher certification. And, as part of this innovative project, Takeda and BioMed Realty have identified common goals and commitments around occupying wellness, energy and water efficiency, and reduced waste to landfills. Moving to 585 Third Street and expanding the presence in Kendall Square will help Takeda achieve its ambitious environmental goals including net-zero greenhouse gas emissions for scopes 1 and 2 by 2035,1 scope 3 GHG emissions, before 20402.

Takeda is committed to allowing its footprint in Massachusetts demonstrates its ways of working with a focus on fostering sustainability, harnessing innovation and offering the best people experience while also creating cost efficiencies. Over the past several years, the company has been deepening its presence in Kendall Square. Construction of 585 Third Street is scheduled to begin in 2023 and Takeda plans to occupy the building starting in 2026.

About Takeda

Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focussing on developing innovative medicines that contribute to the development of a strong, modality-diverse pipeline. Our employees are committed to improving the quality of life for patients and to work with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “release” means this document, any written presentation or written session or any other written discussion or distribution by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This release (including any verbal briefing and no answer to it) is not intended to, and does not constitute, an invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sale or otherwise dispose of, any securities or solicitation of any vote or approval in any jurisdiction. No shares or other securities are offered to the public by means of this release. No offering of securities shall be made in the United States except that the United States Securities Act of 1933, as amended, or an exemption therefrom. This release is not provided (together with any further information which may be provided for the recipient) transaction). Any failure to comply with applicable restrictions may apply. The companies in which Takeda directly and indirectly own investments are separate entities. In this release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include such words as “targets”, “plans”, “consider”, “hopes”, “continues”, “expects”, “discover”, “intends”, “ensure”, “will ”,“ May ”,“ should ”,“ would ”,“ could ”“ anticipates ”,“ estimates ”,“ projects ”or similar expressions or the negative thereof. These forward-looking statements are based on several important factors, including the following, which may indicate that the renewable energy or low carbon energy technology will enable us to reduce our GHG emissions; the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment (s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the US Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and statements of Takeda in this press release may not be indicative of, and not an estimate, forecast, guarantee or projection of Takeda’s future results.

____________________

1 A lack of transparency into, and a significant measure of, these difficulties.

2 Takeda defines carbon neutrality and net zero emissions in accordance with The Greenhouse Gas Protocol. Additional information on our carbon neutrality efforts and other environmental sustainability programs are available at https://www.takeda.com/corporate-responsibility/reporting-on-sustainability/planet/.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker